The Study of Comparison between HbA1c% and Glycated Albumin % in Diabetic ESRD Patients on MHD

Abstract

This study investigated the comparative effectiveness of Glycated Hemoglobin and Glycated Albumin as glycemic control markers in diabetic patients with End Stage Renal Disease undergoing maintenance hemodialysis. The research involved a prospective observational design comparing diabetic nephropathy patients on hemodialysis with diabetic patients having normal renal function. Results demonstrated that Glycated Hemoglobin levels were significantly lower in hemodialysis patients compared to controls, while Glycated Albumin levels remained elevated, suggesting that Glycated Hemoglobin may falsely underestimate glycemic control in patients with renal dysfunction. Multivariate analysis confirmed that Glycated Albumin serves as a more reliable and statistically significant indicator of blood glucose control in this population. The findings indicate that factors affecting red blood cell survival, including severe nephropathy, compromise the accuracy of Glycated Hemoglobin measurements. This study concludes that Glycated Albumin represents a superior biomarker for assessing long-term glycemic status in diabetic patients undergoing hemodialysis treatment.